RadOnc Smart Review

Today, in our final episode on rectal cancer, we'll equip you with practical strategies for managing acute on-treatment toxicities. We'll then delineate evidence-based follow-up schedules, contrasting operative and non-operative approaches. Finally, we'll explore key survivorship considerations, including fertility preservation, bone health, and the crucial role of pelvic floor rehabilitation.

Over the last three episodes, we have constructed the entire modern framework for rectal cancer management. We’ve established when to treat, how to treat, and who to treat with advanced strategies like TNT and immunotherapy. Today, we bring it all to the treatment planning console.This is the practical application episode. We will provide a step-by-step guide to modern rectal cancer contouring based on international consensus. We'll review critical dose constraints you must know. And finally, we will tackle one of the most complex scenarios in our field—using a case to outline a safe and effective approach to pelvic re-irradiation.

In our previous discussions, we've firmly established the role of neoadjuvant radiation therapy for locally advanced rectal cancer. However, radiation, while life-saving, comes with its own set of acute and late toxicities—from sexual dysfunction and infertility to chronic bowel changes and the rare risk of secondary malignancies. This raises a crucial question in modern oncology: for whom can we safely omit radiation, de-escalating treatment without compromising oncologic outcomes? Today, we delve into this concept, focusing on a landmark trial that has reshaped our approach to low-risk rectal cancer: the PROSPECT trial. We'll analyze its design, uncover its key findings, and learn how to identify the specific patient population for whom radiation can potentially be spared.

In our last episode, we explored Total Neoadjuvant Therapy, or TNT, which has revolutionized the management of high-risk locally advanced rectal cancer by increasing pathologic complete response, or pCR, rates and improving distant control. These impressive pCR rates have opened the door to one of the most exciting and debated topics in rectal cancer: avoiding major surgery through "Watch and Wait," or Non-Operative Management. Today, we dive deep into this organ-preserving approach, defining who is a candidate and what surveillance entails. We'll examine key trials like OPRA and data from the International Watch and Wait Database. Finally, we'll shift to a truly groundbreaking development: the highly effective management of mismatch repair deficient, or dMMR, rectal cancer with immunotherapy, which is dramatically changing the treatment landscape for these patients.

In our last episode, we established the foundational principles of neoadjuvant radiation, proving that giving RT before surgery is superior and comparing the short-course and long-course approaches. That framework is perfect for standard-risk disease. But for patients with the highest-risk tumors, the primary driver of mortality isn't local failure—it's distant metastases.This reality has sparked a true revolution in rectal cancer care. Today, we dive into that revolution: Total Neoadjuvant Therapy, or TNT. We will define TNT and its rationale, dissect the blockbuster trials that have redefined the standard of care for high-risk rectal cancer, and cover the game-changing management for biologically distinct dMMR tumors.

In our last episode, we established the fundamental clinical landscape of rectal cancer—the anatomy, the critical role of MRI in staging, and the surgical revolution of Total Mesorectal Excision. We learned that with high-quality TME, surgeons could dramatically reduce local recurrence. The question then became: could we improve upon this new surgical standard?

If there is one disease site that perfectly illustrates the power of multidisciplinary, evidence-based cancer care, it’s rectal cancer. The evolution of its treatment is a masterclass in how surgery, radiation, and chemotherapy can be integrated to dramatically improve outcomes. But before we can appreciate that evolution, we must master the fundamentals.Today, we lay the groundwork for this entire story. We will use a classic case to walk through the essential workup, the critical anatomy that dictates treatment, modern staging with MRI, and finally, the surgical innovation that changed everything—Total Mesorectal Excision.

Today, we conclude our liver mini-series by tackling these crucial topics.F irst, we’ll cover the evidence-based management for biliary tract cancers—including gallbladder cancer and cholangiocarcinoma—with a focus on the patterns of failure that guide our use of adjuvant radiation. Then, we’ll pivot to one of the most common clinical scenarios we face: treating colorectal liver metastases, discussing the role of SBRT in the context of other local therapies.

Today, we conduct our SBRT masterclass for HCC. We will make the definitive case for SBRT over other local therapies by citing the key comparative data. We'll detail the evidence for treating high-risk disease like portal vein thrombosis and walk through the critical dosimetric details—ablative doses, the RTOG 1112 de-escalation schema, and the crucial constraints you need to know to treat safely and effectively.

Welcome back to Rad Onc Smart Review, GI Series.T his is Episode 12: HCC Part 1: The HCC Toolkit – Staging, IR, and Systemic Therapy . Hepatocellular carcinoma, or HCC, is a unique beast in oncology. Unlike most cancers where our focus is solely on the tumor, in HCC we are fighting a war on two fronts: the cancer itself, and the often-diseased liver it inhabits. This dual challenge means that staging and treatment decisions are far more complex than just TNM. Today, we're opening up the HCC toolkit. We'll build a comprehensive framework for managing this disease, starting with the essential staging systems that integrate liver function, like BCLC and Child-Pugh. Then, we’ll tour the interventional radiology suite, comparing TACE, TARE, and RFA. Finally, we'll review the evolution of systemic therapy, from the disappointing early agents to the modern immunotherapy combinations that have transformed the field.